Indian exec gets five years for fakes-making; AZ workers return to picket line;

> A director of Indian pharma company Axon Labs has earned five years in jail for manufacturing phony Sapagun tablets. Article

> The Canadian Pharmaceutical Distribution Network has joined GHX, the Global Healthcare Exchange, to enhance connectivity with its hospital clients. CPDN release

> Drug formulator Bend Research will work with Quotient Clinical to develop compounds for clinical trials and expand options for drug delivery. Bend release

> Ghana has uncovered substandard and counterfeit versions of 13 antimalarial medicines across the country. Story

> Medicago has earned an IRS grant for development work on a Virus-Like Particle vaccine. Medicago release

> AstraZeneca workers in the U.K. are set to return to the picket line. News

> A cut in the value of a Minnesota manufacturing facility and the delay of its sale have had little impact on Genmab, which reported reduced operating losses. Report

> A 15 percent rise in pharma output contributed to a third-quarter boost in Ireland's manufacturing production. Story

> Startup Gallus Biopharmaceuticals plans to buy and expand Johnson & Johnson's Centocor Biologics campus in St. Louis. Article

> Thermo Fisher Scientific has added a 2,000-liter single-use bioreactor to its HyClone line. TFS release

> Tate & Lyle will produce farnesene at its facilities in Decatur, IL, for Amyris. Amyris release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.